Steve Young
About Steve Young
Steve Young, Chief Scientific Officer, is a seasoned professional in clinical data management with a Master's degree in Mathematics from Villanova University, and extensive experience in RBQM and EDC systems across various biopharmaceutical companies.
Title: Chief Scientific Officer
Steve Young is currently serving as the Chief Scientific Officer. In this role, he oversees the strategic direction and scientific operations of the organization. His responsibilities include driving innovation, guiding research initiatives, and ensuring the application of best practices in clinical data management and risk-based monitoring.
Education and Expertise in Mathematics
Steve Young holds a Master’s degree in Mathematics from Villanova University. His educational background in mathematics has equipped him with strong analytical and problem-solving skills, which he has applied throughout his career in clinical data management and biopharmaceutical research.
Background in Biopharmaceutical Companies
Steve Young's professional journey includes 15 years of leadership positions in clinical data management at three biopharmaceutical companies. He has played key roles in the enterprise roll-out of electronic data capture (EDC) systems at Johnson & Johnson and Centocor. These implementations have significantly improved the efficiency and accuracy of data collection and analysis in clinical trials.
Experience with eClinical Solution Providers
Steve Young spent six years working with eClinical solution providers, including Medidata and OmniComm. In these roles, he led the development of analytics and risk-based quality management (RBQM) solutions. His work has been instrumental in advancing the capabilities of eClinical technologies to improve clinical trial management and quality.
Leadership in Risk-Based Monitoring (RBM)
Steve Young has provided risk-based quality management (RBQM) consultation to numerous organizations. He led a pivotal analysis related to risk-based monitoring (RBM) in collaboration with TransCelerate. Currently, he is leading RBQM best-practice initiatives for several industry RBM consortiums, further contributing to the advancement of clinical trial methodologies.